Visit www.wellmark.com for additional drug/class specific clinical criteria, preferred drug
list, and formulary information.
Please ensure member’s name, DOB and ID number are on all additional submitted documents.
Biologicals • Medical records from any physician visit, ED visit, or hospitalization in the past year
• Results from any recent colonoscopy or other relevant GI study if applicable to diagnosis
Esbriet and Ofev • Chart notes, and/or documentation to support diagnosis of idiopathic pulmonary fibrosis
• Results from a high resolution computed tomography (HRCT) study of the chest
• Pathology report from a surgical lung biopsy, if applicable
• Laboratory results: liver function tests
Growth Hormone • Medical records supporting the diagnosis
• Pretreatment growth hormone provocative test result(s) (laboratory report or medical record documentation)
• Pretreatment and/or current IGF-1 level (laboratory report or medical record documentation)
• The following laboratory test reports must be provided:
• diagnostic karyotype results in Turner syndrome
• diagnostic genetic test results in Prader-Willi syndrome
• diagnostic molecular or genetic test results in SHOX deficiency
• Documentation of current anti-retroviral therapy regimen for members with HIV-associated wasting/cachexia
Hepatitis • Complete medical records including: recent progress notes, genotype, subtype, proposed treatment regiment,
liver stage or fibrosis score (including name of scoring system), treatment history, clinical reason that precludes
Harvoni as a treatment option, comorbidities
IVIG • Documentation for why IVIG is not an option for the patient if SQ IG is being requested
• Please attach documentation and lab results: (1) Laboratory evidence of the primary immunodeficiency: total
IgG level or other laboratory evidence such as absence of B lymphocytes (2) Documented inability to mount an
adequate immunologic response to inciting antigens AND (3) Documentation of persistent and severe infections
despite treatment with prophylactic antibiotics
Juxtapid and Kynamro • Laboratory results, chart notes, and/or documentation of genetic or molecular testing to support diagnosis of
homozygous familial hypercholesterolemia
• Untreated baseline and current LDL and triglyceride level
• documentation of current and previous treatment regimen
• For renewal requests, liver function tests with ALT, AST, and bilirubin
Makena • Medical records documenting current gestational age
Pulmonary Arterial
Hypertension
• Report with pretreatment results from right heart catheterization
• Documented date of pulmonary endarterectomy if requesting Adempas for PAH, WHO Group 4 (CTEPH)
PCSK9s • Laboratory results, chart notes, and/or documentation of genetic or molecular testing to support diagnosis of
of familal hypercholesterolemia, if applicable
• Untreated baseline LDL and most recent LDL (within 30 days of request)
• Pharmacy refill history establishing adherence with statin and ezegtimibe
• Medical chart notes documenting contraindications and/or medical reasons that preclude statin use
• Body mass index (BMI)
Synagis • Initiate enrollment by contacting Hy-Vee Pharmacy Solutions at (866) 823-9868
Xolair • Medical records from any physician visits/ED visits in the past year
• The patient’s pretreatment AND current UAS7 urticaria activity score
Viscosupplementation • Synvisc-One is the preferred product
• Initiate enrollment by contacting Hy-Vee Pharmacy Solutions at (877) 794-9833